|Ages Eligible for Study:||16 Years and older|
|Genders Eligible for Study:||Both|
|Accepts Healthy Volunteers:||No|
- Male or female, 16 years or older.
- American Joint Committee on Cancer (AJCC) Stage IV sarcoma with no current radiological evidence of residual disease following either surgery alone or multimodality therapy for treatment of metastatic or relapsed disease. Patients must have presented with either newly diagnosed metastatic sarcoma or distant relapsed disease. Non-surgical local ablative therapies such as SRS or cryotherapy cannot replace surgical resection of disease for purpose of eligibility.
- Histological confirmation of sarcoma, as performed by a pathologist at one of the participating study sites, prior to entry on study.
- Patients who have undergone surgery must have done so within 8 weeks prior to initiation of treatment on this study.
- Patients must have completed radiation or systemic chemotherapy at least 4 weeks prior to treatment on this study.
- Patients previously treated with chemotherapy and/or radiotherapy as part of a multimodality treatment for metastatic disease must have recovered from all adverse effects of treatment or have returned to baseline status.
- Imaging study performed within 4 weeks prior to administration of first vaccination documenting that patient has no evidence of disease. Study must include CT scan of chest, abdomen, and pelvis.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1.
- Weight ≥ 40 kg.
Have organ and marrow function as defined below:
WBC ≥ 3.0 cells/mm3 Platelets ≥ 100,000/mm3 Total bilirubin ≤ 2.0 mg/dL AST (SGOT)/ALT (SGPT) ≤ 1.5 x ULN
- Current use of an acceptable form of birth control.
- Ability to understand English and to provide written informed consent and authorization for protected health information disclosure whether by self or by legally authorized representative.
- Patients who develop locally recurrent disease only with no evidence of distant metastatic disease at the time of relapse.
- Evidence of local or metastatic disease or who are not disease free at the time of the first vaccination.
- Patients with Ewing sarcoma, rhabdomyosarcoma, or gastrointestinal stromal tumors.
- Patients previously treated with KLH or ganglioside containing vaccines or monoclonal antibodies (mAbs) against gangliosides.
- Females of childbearing potential that are pregnant or intend to become pregnant or who are breastfeeding. Females must have negative βHCG test within two weeks of first vaccination.
- Current active malignancy or history of malignancy, other than sarcoma, within the past two years, except for cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma that has been surgically removed or prostate cancer that is being managed by watchful waiting.
- Any medical condition that may limit the ability of the patient to complete the full course of treatment or to respond immunologically to vaccination, (including autoimmune or neurodegenerative disorders such as multiple sclerosis and amyotrophic lateral sclerosis).
- Patients requiring repeated or continuous doses of anti-inflammatory medications (steroids, non-steroidal anti-inflammatory drugs, or full dose aspirin). Episodic use of steroids or non-steroidal anti-inflammatory drugs permitted as long as they are not given within one week prior to or following vaccine administration. Continuous dosing of low-dose aspirin (≤ 81 mg/day) is acceptable.
- Use of or treatment with a drug that has not received regulatory approval or participation in a drug or device study during the 28 days preceding the first vaccination.
- Known history of HIV-positivity OR serologic evidence of HIV at screening or any other immunodeficiency disorders or illnesses. Serologic positivity for the Hepatitis B Virus (HBV) or the Hepatitis C Virus (HCV), unless explained by a documented vaccination.
- Inability or unwillingness to meet the attendance requirements of the study.
- Any clinically significant abnormal finding at Screening (as determined by the Principal Investigator, in consultation with the Medical Monitor and the Sponsor), that would interfere with study participation, that would interfere with the evaluation or quality of the data, or that would put the patient at increased risk of illness or injury.